z-bio 2025-07-03 2628

　　On June 5, 2025, Sichuan Kelunbotai Biopharma Co., Ltd. (hereinafter referred to as "Kolbotai" or "Company", 6990.HK) announced that it would issue 5,918,000 H shares under general authorization, accounting for approximately 2.54% of the company's total share capital after issuance, with an allotment price of HK$331.8 and a net raised amount of approximately US$250 million.

　　This placement:

　　It has been widely recognized by various investment institutions at home and abroad, and has been actively subscribed by high-quality investors such as international long-term, sovereign funds and medical special funds. The order scale exceeds the scale of this financing;

　　Due to strong demand for bookkeeping, the transaction size increased from the initially set US$200 million to US$250 million, becoming the largest new stock issuance transaction in the biopharmaceutical industry in the Hong Kong stock market in the past 12 months;

　　The allocation price is 7.58% discount from yesterday's closing price, and a premium of 0.89% from the average closing price of the previous five days.

　　The financing amount plan is mainly used for product research and development, clinical trials, registration, manufacturing and commercialization, and will further enhance the company's internal R&D technical capabilities, strengthen external cooperation and expand product pipeline portfolio.

　　Dr. Ge Junyou, CEO of Columbotai, said, "I am very happy to see that this placement has received continuous support from the company's important existing shareholders, and also expands new heavyweight investors. This is a reflection of the long-term investment value of Columbotai being recognized by the international capital market and various professional investors. We plan to provide support for the company to strengthen its product pipeline layout and accelerate global clinical progress through this financing. This move will help accelerate the company's value exploration of cutting-edge therapies in the industry and benefit more oncology patients."

　　About Colombotai

　　Sichuan Kelunbotai Biopharma Co., Ltd. (hereinafter referred to as "Kolbotai Biopharma", stock code: 6990.HK) is a subsidiary of Kelun Pharmaceutical, focusing on the research and development, production, commercialization and international cooperation of innovative biotechnology drugs and small molecule drugs. Focusing on unmet clinical needs around the world and China, the company focuses on major diseases such as tumors, autoimmunity, inflammation and metabolism, builds an international drug research and development and industrialization platform, and is committed to becoming an international leading enterprise in the field of innovative drugs. The company currently has more than 30 key innovative drug projects, of which 3 have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has successfully built the internationally renowned proprietary ADC development platform OptiDCTM. One ADC project has been approved for marketing, one ADC project is in the NDA stage, and multiple ADC and new coupling drug projects are in the clinical or preclinical research stage. For more information, please visit the official website https://kelun-biotech.com/.